Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.
A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.